CollPlant Biotechnologies (CLGN) lifts share capital, files new resale opinion

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. reports that its shareholders have approved an increase in authorized share capital from 30,000,000 to 500,000,000 ordinary shares, each with a par value of NIS 1.50, together with an amendment to its Amended and Restated Memorandum and Articles of Association.

Following this approval, the company has filed an updated opinion from Goldfarb Gross Seligman & Co. on the validity of ordinary shares registered for resale under its Registration Statement on Form F-3 (File No. 333-297347), and this report and its exhibits are incorporated by reference into that registration statement.

Key Figures

Authorized share capital before increase: 30,000,000 ordinary shares Authorized share capital after increase: 500,000,000 ordinary shares Par value per ordinary share: NIS 1.50 per share +1 more

4 metrics

Authorized share capital before increase 30,000,000 ordinary shares Authorized ordinary share capital prior to shareholder approval

Authorized share capital after increase 500,000,000 ordinary shares Authorized ordinary share capital following shareholder approval

Par value per ordinary share NIS 1.50 per share Par value of CollPlant ordinary shares before and after capital increase

Form F-3 file number 333-297347 SEC file number for the Registration Statement into which this report is incorporated

Key Terms

authorized share capital, ordinary shares, Registration Statement on Form F-3, Memorandum and Articles of Association, +2 more

6 terms

authorized share capital financial

"approved an increase in the Company’s authorized share capital from 30,000,000 ordinary shares"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

ordinary shares financial

"from 30,000,000 ordinary shares, par value NIS 1.50 per share, to 500,000,000 ordinary shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Registration Statement on Form F-3 regulatory

"ordinary shares registered for resale pursuant to the Company’s Registration Statement on Form F-3"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

Memorandum and Articles of Association regulatory

"approved the corresponding amendment to the Company’s Amended and Restated Memorandum and Articles of Association"

Memorandum and articles of association are the founding legal documents of a company: the memorandum sets out the company’s basic purpose and scope, while the articles act as its internal rulebook detailing how the company is run, who has what powers, and how decisions are made. For investors these documents matter because they define ownership rights, voting rules, limits on activities, and procedures for major changes—like a contract and rulebook that determine how their investment can be used and protected.

opinion of counsel regulatory

"filing an updated opinion of Goldfarb Gross Seligman & Co., counsel to the Company"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/06/2026 - 04:06 PM Accepted by SEC EDGAR 08/06/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What change to share capital did CollPlant Biotechnologies (CLGN) report in this Form 6-K?

CollPlant Biotechnologies reported shareholder approval to increase its authorized share capital from 30,000,000 to 500,000,000 ordinary shares. The par value of NIS 1.50 per share remains unchanged, and the company amended its Amended and Restated Memorandum and Articles of Association accordingly.

What is the par value of CollPlant Biotechnologies (CLGN) ordinary shares after the capital increase?

The par value of CollPlant’s ordinary shares remains NIS 1.50 per share after the increase in authorized share capital. Only the authorized number of shares changed, from 30,000,000 to 500,000,000, as approved by shareholders and reflected in updated corporate documents.

Why did CollPlant Biotechnologies (CLGN) file an updated legal opinion with this report?

CollPlant filed an updated opinion from Goldfarb Gross Seligman & Co. regarding the validity of ordinary shares registered for resale. This opinion relates to shares covered by its Registration Statement on Form F-3 and reflects the newly approved authorized share capital structure.

How is this CollPlant Biotechnologies (CLGN) Form 6-K related to its Form F-3 registration statement?

This Form 6-K, including Exhibits 5.1 and 23.2, is incorporated by reference into CollPlant’s Registration Statement on Form F-3 (File No. 333-297347). It supplies an updated legal opinion on the validity of ordinary shares registered for resale under that shelf registration.

What exhibits are included with CollPlant Biotechnologies (CLGN) August 2026 Form 6-K?

The report includes Exhibit 5.1, an opinion of Goldfarb Gross Seligman & Co., and Exhibit 23.2, the firm’s consent contained within Exhibit 5.1. Both exhibits support the validity of ordinary shares registered for resale under CollPlant’s Form F-3.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

This Form 6-K, including Exhibits 5.1 and 23.2 hereto, is hereby incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-297347) to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

As previously reported in the Company’s Report on Form 6-K furnished to the U.S. Securities and Exchange Commission on July 29, 2026, the shareholders of CollPlant Biotechnologies Ltd. (the “Company”) approved an increase in the Company’s authorized share capital from 30,000,000 ordinary shares, par value NIS 1.50 per share, to 500,000,000 ordinary shares, par value NIS 1.50 per share, and approved the corresponding amendment to the Company’s Amended and Restated Memorandum and Articles of Association.

Following receipt of such shareholder approval, the Company is filing an updated opinion of Goldfarb Gross Seligman & Co., counsel to the Company, regarding the validity of the ordinary shares registered for resale pursuant to the Company’s Registration Statement on Form F-3 (File No. 333-297347), which opinion is attached hereto as Exhibit 5.1

EXHIBITS

Exhibit No.		Description
5.1		Opinion of Goldfarb Gross Seligman & Co.
23.2		Consent of Goldfarb Gross Seligman & Co. (contained in Exhibit 5.1)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: August 6, 2026	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

2

Filing Exhibits & Attachments

1 document

Other Documents

• EX-5.1 OPINION OF GOLDFARB GROSS SELIGMAN & CO 10.8 KB